Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Hold” from analysts covering the stock, according to data from Marketbeat.com. The analysis comes from seven research firms, with four analysts suggesting a hold position and three recommending a buy. The average one-year price target for the company is $80.60, reflecting varied expectations among financial experts.
Several brokerages have recently adjusted their price targets for Prestige. Oppenheimer lowered its price target from $82.00 to $72.00 while maintaining an “outperform” rating in a report dated October 21, 2023. Canaccord Genuity Group also revised its target from $100.00 to $88.00, endorsing a “buy” rating in a research note released on November 7, 2023. Meanwhile, Zacks Research upgraded the company from a “strong sell” to a “hold” rating on November 10, 2023.
Analysts from Jefferies Financial Group cut their price target from $70.00 to $66.00, reaffirming a “hold” rating in a report on January 30, 2024. Additionally, on January 22, 2024, Weiss Ratings reissued a “hold (c)” rating on Prestige Consumer Healthcare, indicating a cautious outlook for the stock.
Investor Activity and Company Performance
Recent trading activity reveals significant interest from institutional investors in Prestige Consumer Healthcare. AQR Capital Management LLC increased its stake by 11.9% during the first quarter, now holding 30,056 shares valued at approximately $2.56 million. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. also raised its holdings by 4.6%, owning 29,490 shares valued at $2.54 million.
Moreover, Goldman Sachs Group Inc. boosted its stake by a notable 28.4%, acquiring an additional 120,965 shares to reach a total of 546,672 shares valued at about $46.99 million. Jane Street Group LLC significantly increased its holdings by 204.0%, now owning 104,802 shares valued at around $9.01 million. Currently, institutional investors own 99.95% of the stock.
On February 5, 2026, Prestige Consumer Healthcare announced its quarterly earnings, reporting an earnings per share (EPS) of $1.14, which fell short of analysts’ consensus estimate of $1.16 by $0.02. The company’s revenue for the quarter was approximately $283.44 million, also below the expected $286.93 million. Compared to the same quarter last year, revenue declined by 2.4%, with the previous year’s EPS recorded at $1.22. The company has forecasted an EPS of $4.540 for its fiscal year 2026.
Company Overview and Market Position
Prestige Consumer Healthcare is a prominent manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company specializes in the development and commercialization of a diverse range of non-prescription remedies that address various consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care, and women’s health.
Key brands within Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief), and TheraTears (dry eye therapy). These products are designed to meet common health concerns among consumers, solidifying Prestige’s position in the healthcare market.
As analysts continue to assess Prestige Consumer Healthcare’s performance and market potential, investors will be closely monitoring the company’s strategies and upcoming financial disclosures for insights into its growth trajectory.
